[go: up one dir, main page]

MXPA05004074A - Nuevos adenovirus, acidos nucleicos que los codifican y su uso. - Google Patents

Nuevos adenovirus, acidos nucleicos que los codifican y su uso.

Info

Publication number
MXPA05004074A
MXPA05004074A MXPA05004074A MXPA05004074A MXPA05004074A MX PA05004074 A MXPA05004074 A MX PA05004074A MX PA05004074 A MXPA05004074 A MX PA05004074A MX PA05004074 A MXPA05004074 A MX PA05004074A MX PA05004074 A MXPA05004074 A MX PA05004074A
Authority
MX
Mexico
Prior art keywords
protein
adenovirus expressing
reverse order
expressing genes
group
Prior art date
Application number
MXPA05004074A
Other languages
English (en)
Inventor
Sonne Holm Per
Original Assignee
Sonne Holm Per
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/005583 external-priority patent/WO2003099859A2/de
Application filed by Sonne Holm Per filed Critical Sonne Holm Per
Publication of MXPA05004074A publication Critical patent/MXPA05004074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion esta relacionada con un adenovirus que expresa una primera proteina que esta seleccionada del grupo que comprende una proteina E1B y una proteina E4, antes que una segunda proteina que esta seleccionada del grupo que comprende una proteina E1A.
MXPA05004074A 2002-10-15 2003-10-15 Nuevos adenovirus, acidos nucleicos que los codifican y su uso. MXPA05004074A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10248039 2002-10-15
DE10322530 2003-05-19
DE10324085 2003-05-27
PCT/EP2003/005583 WO2003099859A2 (de) 2002-05-27 2003-05-27 Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
PCT/EP2003/011427 WO2004035616A2 (de) 2002-10-15 2003-10-15 Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon

Publications (1)

Publication Number Publication Date
MXPA05004074A true MXPA05004074A (es) 2005-09-20

Family

ID=32314683

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05004074A MXPA05004074A (es) 2002-10-15 2003-10-15 Nuevos adenovirus, acidos nucleicos que los codifican y su uso.

Country Status (9)

Country Link
US (1) US8951772B2 (es)
EP (1) EP1554375B1 (es)
AU (1) AU2010257327C1 (es)
DK (1) DK1554375T3 (es)
MX (1) MXPA05004074A (es)
PL (1) PL219321B1 (es)
SG (1) SG165168A1 (es)
WO (1) WO2004035616A2 (es)
ZA (1) ZA200502680B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
CN101570764A (zh) 2001-10-19 2009-11-04 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
KR101083450B1 (ko) 2002-05-27 2011-11-16 페르 손네 홀름 아데노바이러스 및 그를 코딩하는 핵산의 신규 용도
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
WO2006070024A2 (de) * 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
EP1831382B1 (en) * 2004-12-31 2023-01-18 Per Sonne Holm Method for reversing multiple resistance in animal cells
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
KR20210031852A (ko) * 2018-03-05 2021-03-23 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료
AU2019294294A1 (en) * 2018-06-25 2021-02-11 Fondazione Telethon Ets Gene therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
DE10015413A1 (de) * 2000-03-23 2001-09-27 Max Delbrueck Centrum Mittel zur Diagnose und Therapie viraler Erkrankungen
WO2002042468A2 (en) * 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
US20030095989A1 (en) * 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
CA2433071C (en) * 2000-12-28 2011-02-15 Per Sonne Holm Use of transcription factor yb-1 in adenoviral systems
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways

Also Published As

Publication number Publication date
US8951772B2 (en) 2015-02-10
AU2010257327B2 (en) 2011-09-29
PL219321B1 (pl) 2015-04-30
EP1554375A2 (de) 2005-07-20
US20060057113A1 (en) 2006-03-16
SG165168A1 (en) 2010-10-28
AU2010257327C1 (en) 2012-02-16
WO2004035616A3 (de) 2004-05-27
EP1554375B1 (de) 2018-08-22
ZA200502680B (en) 2005-11-30
AU2010257327A1 (en) 2011-01-13
DK1554375T3 (en) 2018-12-17
WO2004035616A2 (de) 2004-04-29
PL376573A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
Chang et al. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
ATE310829T1 (de) Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus
ATE540686T1 (de) Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO2003099859A3 (de) Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
CA2478616A1 (en) Use of adenoviruses mutated in the va genes for cancer treatment
DK1121137T3 (da) Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter
BRPI0513855A (pt) células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus
CA2449013A1 (en) Viral mutants that selectively replicate in targeted human cancer cells
DE60237013D1 (de) Replizierende adenovirus-vektoren
NO20021634L (no) Fremstilling av rekombinante adenoviruser og adenovirusbanker
WO2004018002A3 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
WO2001072341A3 (en) Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
FR2835429B1 (fr) Utilisation d'acide ascorbique pour renforcer la cohesion de la jonction dermo-epidermique
AU3880900A (en) Surface localized colligin/hsp47 in carcinoma cells
WO2003077841A3 (en) Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
WO2004043406A3 (en) ENGINEERED RNAi ADENOVIRUS SILENCING EXPRESSION (ERASE) OF DNA REPAIR PROTEINS
EP1607483A4 (en) RECOMBINANT PRODUCT CONSTRUCTED FROM A VIRAL VECTOR AND A HUMAN TUMOR SUPPRESSOR GENE AND USE OF THE RECOMBINANT PRODUCT
WO2002042325A3 (en) Cyp1b1 nucleic acids and methods of use
EP2172552A3 (en) Recombinant nucleic acids comprising regions of AD6
RU2351361C2 (ru) Новое применение аденовируса и кодирующих его нуклеиновых кислот
DE60023915D1 (de) Replikationsprotein-a-bindendes transkriptionsfaktor (rbt1) und dessen verwendungen

Legal Events

Date Code Title Description
FG Grant or registration